CA2538856A1 - Transdermal pharmaceutical formulation for minimizing skin residues - Google Patents

Transdermal pharmaceutical formulation for minimizing skin residues Download PDF

Info

Publication number
CA2538856A1
CA2538856A1 CA002538856A CA2538856A CA2538856A1 CA 2538856 A1 CA2538856 A1 CA 2538856A1 CA 002538856 A CA002538856 A CA 002538856A CA 2538856 A CA2538856 A CA 2538856A CA 2538856 A1 CA2538856 A1 CA 2538856A1
Authority
CA
Canada
Prior art keywords
anti
glycol
drugs
present
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002538856A
Other languages
French (fr)
Other versions
CA2538856C (en
Inventor
Dario Norberto R. Carrara
Arnaud Grenier
Celine Besse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antares Pharma IPL AG
Original Assignee
Antares Pharma Ipl Ag
Dario Norberto R. Carrara
Arnaud Grenier
Celine Besse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US51061303P priority Critical
Priority to US60/510,613 priority
Application filed by Antares Pharma Ipl Ag, Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse filed Critical Antares Pharma Ipl Ag
Priority to PCT/EP2004/011175 priority patent/WO2005039531A1/en
Publication of CA2538856A1 publication Critical patent/CA2538856A1/en
Application granted granted Critical
Publication of CA2538856C publication Critical patent/CA2538856C/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links